{
 "meta": {
  "api_version": "1.0.0",
  "dataset_version": "2.0.1",
  "corpus_snapshot": "2026-10-12T22:59:14+0200",
  "source_commit": "93739c9d195dc39e47eecfabc3cab2565a2f256f",
  "license": "CC-BY-4.0",
  "cite": "Barton O. Oliver's mTOR Atlas. doi:10.5281/zenodo.22059963",
  "docs": "https://mtor-atlas.org/api/"
 },
 "data": {
  "id": "TEM-RCC",
  "claim": "Temsirolimus inhibits Renal cell carcinoma (RCC)",
  "source": {
   "name": "Temsirolimus",
   "entity": "temsirolimus"
  },
  "target": {
   "name": "Renal cell carcinoma (RCC)",
   "entity": "renal-cell-carcinoma-rcc"
  },
  "effect": "inhibits",
  "type": "clinical-outcome",
  "directness": "indirect",
  "timescale": "chronic",
  "compartment": null,
  "map_band": "outcome",
  "species": [
   "human"
  ],
  "mechanism": "In poor-prognosis renal cancer, temsirolimus improved overall survival against interferon - the hardest endpoint there is.",
  "mechanism_beginner": "In hard-to-treat kidney cancer, temsirolimus helped patients live longer compared with an older drug.",
  "context": null,
  "boundary": "Poor-prognosis patients specifically; the combination arm did not beat temsirolimus alone.",
  "note": "Overall survival, not a surrogate. Worth pointing at.",
  "consensus_contested": false,
  "curation_contested": false,
  "contested": false,
  "confidence": {
   "mechanistic": "high",
   "human_relevance": "established",
   "consensus": "established"
  },
  "evidence": {
   "kind": "Pharmacological",
   "strongest": {
    "code": "H",
    "label": "Human study"
   },
   "supporting": [
    "HUD2007"
   ],
   "conflicting": []
  },
  "external_refs": [],
  "reviewed": null,
  "updated": null,
  "checked": null,
  "review_status": "unreviewed",
  "reviewer": null,
  "curation_status": "Proposed",
  "url": "https://mtor-atlas.org/relation/TEM-RCC/",
  "api_url": "https://mtor-atlas.org/api/v1/relations/TEM-RCC.json"
 }
}